Immunocompromised patients and COVID-19 : how do we protect those most at risk?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert review of anti-infective therapy - 22(2024), 1-3 vom: 14. Jan., Seite 1-3 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schneider, Jochen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14787210.2023.2296067 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365881937 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365881937 | ||
| 003 | DE-627 | ||
| 005 | 20240214233010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14787210.2023.2296067 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM365881937 | ||
| 035 | |a (NLM)38097501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schneider, Jochen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunocompromised patients and COVID-19 |b how do we protect those most at risk? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a risk for severe COVID-19 | |
| 700 | 1 | |a Erber, Johanna |e verfasserin |4 aut | |
| 700 | 1 | |a Renders, Lutz |e verfasserin |4 aut | |
| 700 | 1 | |a Spinner, Christoph D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anti-infective therapy |d 2003 |g 22(2024), 1-3 vom: 14. Jan., Seite 1-3 |w (DE-627)NLM151540101 |x 1744-8336 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1-3 |g day:14 |g month:01 |g pages:1-3 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14787210.2023.2296067 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1-3 |b 14 |c 01 |h 1-3 | ||